Lineage Cell Therapeutics
LCTX
115 hedge funds and large institutions have $105M invested in Lineage Cell Therapeutics in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 13 closing their positions.
2,925% more call options, than puts
Call options by funds: $121K | Put options by funds: $4K
85% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 13
37% more capital invested
Capital invested by funds: $76.2M → $105M (+$28.4M)
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
8% more funds holding
Funds holding: 106 → 115 (+9)
2.64% more ownership
Funds ownership: 38.32% → 40.96% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$2.01M |
| 2 |
Millennium Management
New York
|
+$1.4M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$897K |
| 4 |
Jane Street
New York
|
+$635K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$555K |
Top Sellers
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$237K |
| 2 |
E
Ergoteles
New York
|
-$220K |
| 3 |
Man Group
London,
United Kingdom
|
-$143K |
| 4 |
Lazard Asset Management
New York
|
-$107K |
| 5 |
BlackRock
New York
|
-$104K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
1832 Asset Management
Toronto,
Ontario, Canada
| – | -$5 | -5 | Closed |
|
LCTX Hedge Fund Activity: Q1 2023 in Review
115 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2023, worth a combined $105M — up 37% from $76.2M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new LCTX positions and 13 closed out — a net gain of 11 holders — while 26 added to existing stakes and 21 trimmed.
The largest buyer was Bank of America, adding an estimated $2.01M. The largest seller was Jacobs Levy Equity Management, exiting entirely with an estimated $237K sold.
- 115 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2023, up from 106 in Q4 2022.
- Funds reported $105M of Lineage Cell Therapeutics stock for Q1 2023, up 37% quarter-over-quarter.
- 24 funds opened new Lineage Cell Therapeutics positions in Q1 2023 and 13 closed out, a net change of +11 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2023 was Bank of America, an estimated $2.01M added.
- The largest Lineage Cell Therapeutics seller in Q1 2023 was Jacobs Levy Equity Management, an estimated $237K sold.
Based on aggregated 13F filings for Q1 2023.